6008-91-9 Usage
Description
[(2R,3R,4R,5R)-5-(6-aminopurin-9-yl)-4-hydroxy-2-[[hydroxy-[hydroxy-[3-hydroxy-2,2-dimethyl-3-[2-[2-(2-methylprop-2-enoylsulfanyl)ethylcarbamoyl]ethylcarbamoyl]propoxy]phosphoryl]oxy-phosphoryl]oxymethyl]oxolan-3-yl]oxyphosphonic acid is a complex organic compound with a unique molecular structure. It is characterized by its chiral centers at the 2nd, 3rd, 4th, and 5th positions, which are all in the R configuration. [(2R,3R,4R,5R)-5-(6-aminopurin-9-yl)-4-hydroxy-2-[[hydroxy-[hydroxy-[3-hydroxy-2,2-dimethyl-3-[2-[2-(2-methylprop-2-enoylsulfanyl)ethylcarbamoyl]ethylcarbamoyl]propoxy]phosphoryl]oxy-phosphoryl]oxymethyl]oxolan-3-yl]oxyphosphonic acid contains various functional groups, including hydroxyl, amino, and phosphoryl groups, as well as a 6-aminopurine moiety. This intricate structure likely confers specific biological activities and potential applications in various fields.
Uses
Used in Pharmaceutical Industry:
[(2R,3R,4R,5R)-5-(6-aminopurin-9-yl)-4-hydroxy-2-[[hydroxy-[hydroxy-[3-hydroxy-2,2-dimethyl-3-[2-[2-(2-methylprop-2-enoylsulfanyl)ethylcarbamoyl]ethylcarbamoyl]propoxy]phosphoryl]oxy-phosphoryl]oxymethyl]oxolan-3-yl]oxyphosphonic acid is used as a pharmaceutical agent for its potential therapeutic effects. The presence of the 6-aminopurine moiety suggests that it may have activity against certain diseases, possibly through modulation of purine metabolism or interaction with purine receptors. Its complex structure and functional groups may also enable it to target specific biological pathways or cellular processes, making it a promising candidate for the development of new drugs.
Used in Chemical Research:
In the field of chemical research, [(2R,3R,4R,5R)-5-(6-aminopurin-9-yl)-4-hydroxy-2-[[hydroxy-[hydroxy-[3-hydroxy-2,2-dimethyl-3-[2-[2-(2-methylprop-2-enoylsulfanyl)ethylcarbamoyl]ethylcarbamoyl]propoxy]phosphoryl]oxy-phosphoryl]oxymethyl]oxolan-3-yl]oxyphosphonic acid can serve as a model compound for studying the synthesis and reactivity of complex organic molecules. Its chiral centers and diverse functional groups provide opportunities for exploring enantioselective synthesis, as well as the development of new synthetic methods and strategies for the preparation of biologically active compounds.
Used in Material Science:
[(2R,3R,4R,5R)-5-(6-aminopurin-9-yl)-4-hydroxy-2-[[hydroxy-[hydroxy-[3-hydroxy-2,2-dimethyl-3-[2-[2-(2-methylprop-2-enoylsulfanyl)ethylcarbamoyl]ethylcarbamoyl]propoxy]phosphoryl]oxy-phosphoryl]oxymethyl]oxolan-3-yl]oxyphosphonic acid may also find applications in material science, particularly in the development of new materials with unique properties. Its ability to form hydrogen bonds and coordinate with metal ions could potentially be exploited to create self-assembling systems, supramolecular structures, or materials with specific catalytic, sensing, or optical properties.
Check Digit Verification of cas no
The CAS Registry Mumber 6008-91-9 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 6,0,0 and 8 respectively; the second part has 2 digits, 9 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 6008-91:
(6*6)+(5*0)+(4*0)+(3*8)+(2*9)+(1*1)=79
79 % 10 = 9
So 6008-91-9 is a valid CAS Registry Number.
InChI:InChI=1/C25H40N7O17P3S/c1-13(2)24(37)53-8-7-27-15(33)5-6-28-22(36)19(35)25(3,4)10-46-52(43,44)49-51(41,42)45-9-14-18(48-50(38,39)40)17(34)23(47-14)32-12-31-16-20(26)29-11-30-21(16)32/h11-12,14,17-19,23,34-35H,1,5-10H2,2-4H3,(H,27,33)(H,28,36)(H,41,42)(H,43,44)(H2,26,29,30)(H2,38,39,40)/t14-,17-,18-,19+,23-/m1/s1
6008-91-9Relevant articles and documents
METHODS (AMACR)
-
Paragraph 0190; 0191, (2017/07/14)
A method of measuring α-methylacyl-CoA racemase (AMACR) activity in a sample is described comprising the steps of: (i) providing a sample; (ii) contacting said sample with a substrate compound that undergoes elimination of hydrogen and a leaving group catalysed by said AMACR to produce a product compound having an additional carbon-carbon double bond; and (iii) measuring the amount of said leaving group and/or of said product compound and/or of unreacted substrate compound. Also provided are methods of diagnosis and medical imaging, in particular for use in diagnosing prostate cancer. Also provided are substrate compounds of Formula 1 for use in the methods described herein.
